Delivery Order SPE2DB24D8002-SPE2DB24FJMPU

Award Date 7/17/24
Potential Completion Date 7/18/24
Potential Value $1.3K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Anoka, MN, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business. The contract, valued at $3,317.13, is for the delivery of the pharmaceutical product Fluticasone-Salmeterol 115-21 12GM. The contract has an ultimate completion date of February 25, 2025. Dakota Drug, Inc. holds a significant single-award Indefinite Delivery Contract (IDC) with the DLA, SPE2DB24D8001, valued at $999,999,999.00, as...
This contract award, valued at $1,524.99, was issued by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business. The contract is for the delivery of Fluticasone-Salmeterol 115-21 12GM, a pharmaceutical product. The contract is a Delivery Order, with a Firm Fixed Price pricing type, and an ultimate completion date of February 13, 2025. Dakota Drug, Inc. holds a larger, single-award Indefinite Delivery Contract (IDC) with the DLA, valued at...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business. The $2,437.20 firm fixed-price delivery order contract is for the supply of Fluticasone-Salmeterol 115-21 12GM, a pharmaceutical product. The contract has an ultimate completion date of June 3, 2024. Dakota Drug, Inc. is an established vendor in the federal medical supply market, holding a $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA...
This federal contract award, identified as SPE2DB24D8003 and SPE2DB25FJTJM, was issued by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business registered in SAM.gov. The award, valued at $3,304.98, is for the delivery of fluticasone-salmeterol 115-21 12GM pharmaceutical products. This contract has an ultimate completion date of November 29, 2024, and is a firm fixed-price delivery order contract. Dakota Drug, Inc. is a key supplier for the DLA...
This federal contract award, valued at $2,698.33, was issued by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business. The contract is a delivery order for Fluticasone-Salmeterol 230-21 12GM, a pharmaceutical product, with a performance period ending on March 8, 2024. Dakota Drug, Inc. is a key supplier to the DLA's Troop Support Medical division, holding a $999,999,999.00 Indefinite Delivery Contract (IDC) as part of the DLA Troop Support...
This federal contract award, valued at $3,405.30, was issued by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business. The contract is for the delivery of fluticasone-salmeterol 115-21 12GM pharmaceutical products, which are likely used for respiratory conditions. The contract has an ultimate completion date of April 10, 2025 and is a firm fixed-price delivery order. Dakota Drug, Inc. has a significant single-award Indefinite Delivery Contract...
This is a firm fixed price delivery order contract awarded by the Defense Logistics Agency (DLA) Troop Support Medical to Dakota Drug, Inc., a self-certified small disadvantaged business operating as a for-profit subchapter S corporation. The contract, valued at $2,538.99, is for the delivery of the pharmaceutical product fluticasone-salmeterol 500-50 60s. This award is associated with Dakota Drug, Inc.'s Indefinite Delivery Contract (IDC) SPE2DB24D8001, valued at $999,999,999.00, which allows...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business. The contract, valued at $3,476.84, is for the delivery of Fluticasone-Salmeterol 45-21 12GM, a pharmaceutical product. The contract does not have a set-aside designation and is set to be completed by October 29, 2024. Dakota Drug, Inc. is a key supplier to the DLA Troop Support Medical division, providing a range of pharmaceutical...
This contract award, identified as SPE2DX15D8002|SPE2DX24F2WN0, was issued by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business. The $4,274.76 firm fixed-price delivery order is for the provision of fluticasone-salmeterol 230-21 12GM, a pharmaceutical product used for respiratory conditions. The award is not associated with a larger contract vehicle, and there is no set-aside designation. Dakota Drug, Inc. is the prime contractor, and there...
This federal contract award, SPE2DB24D8003|SPE2DB25FJTNP, was issued by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business. The contract is for the delivery of fluticasone-salmeterol 230-21 12GM pharmaceutical products. The award has a ceiling value of $9,501.67 and is a Firm Fixed Price delivery order contract with a period of performance through December 31, 2024. This award is not associated with a set-aside program. Dakota Drug, Inc. is...
  • SPE2DB24D8002
    Indefinite Delivery Contract
  • SPE2DB24D8002-SPE2DB24FJMPU
    Delivery Order

This federal contract award, identified as SPE2DB24D8002|SPE2DB24FJMPU, was issued by the Defense Logistics Agency (DLA) Troop Support Medical to the prime contractor, Dakota Drug, Inc. The contract is a firm fixed-price delivery order for the delivery of pharmaceutical products, specifically Fluticasone-Salmeterol 115-21 12GM. The total ceiling value of the contract is $1,256.94, and the ultimate completion date is July 18, 2024.

Dakota Drug, Inc. is a self-certified small disadvantaged business that operates as a for-profit subchapter S corporation. The company has significant experience in providing pharmaceutical products, medical supplies, and healthcare equipment to the U.S. Department of Defense. This award is associated with Dakota Drug, Inc.'s larger Indefinite Delivery Contract (IDC) with the DLA, identified as SPE2DB24D8001, which is valued at $999,999,999.00. This IDC allows Dakota Drug, Inc. to supply a comprehensive range of medical items to support the DLA Troop Support Medical's ECAT Generation V Program, which focuses on procuring commercial medical equipment, accessories, consumables, and medical simulation equipment.

Generated 10/16/24, 9:33 AM